Overview

SHARP for over 30 years has been at the forefront of the prevention of cardiovascular disease in Scotland. As we emerge from the effects of the COVID-19 pandemic our exciting educational programme continues with our November 2021 meeting.

Atrial fibrillation is a major risk factor for stroke. We will address both its detection and management, how to balance the benefit of prevention versus the risks and what is new in respect of national clinical guidance. The long term mortality and morbidity effects of coronary artery disease remains a major problem for society so it is both appropriate and important using a personalised approach, to examine recent therapeutic developments of heart failure in improving clinical outcomes.

We have become accustomised in the past two years to the benefits of technology enhanced consulting but wearable technology in the detection of heart disease continues to develop apace. Those attending the meeting will learn the role of technology in diagnosis and importantly what to do when faced with a printout from a patient using the latest ‘gizmo’.

We always need to look forward and more especially after a difficult two years. We are fortunate to have as a speaker, a worldwide expert of how the use of data will inform the management of patients with heart and vascular disease in the years ahead.

Finally, we are very proud of our continuing role in promoting the SHARP prize in the field of cardiovascular disease in order to showcase the work of young health professionals and helping to support and enhance their careers.